Creo Medical Group Plc · LSE:CREO
Creo Medical — H1 2025 Earnings Presentation
19 slides from Creo Medical's earnings presentation, 2025
Slide 1: Leading in Advanced Flexible Endoscopy
Creo Medical Leading in Advanced Flexible Endoscopy Results for the 6 months ended 30 June 2025 © Creo Medical 2025. All rights reserved.
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE This presentation, which has been prepared by, and is the sole responsibility of, Creo Medical Group plc (the "Company"), has been prepared solely in connection with the Company's unaudited half year results for the 6 months to 30 June 2025. For the purposes of this notic
Slide 3: Overview
Overview CREO MEDICAL
Slide 4: Improving patient outcomes through surgical endoscopy
Improving patient outcomes through surgical endoscopy • Multi-indication platform across Gastrointestinal, Advanced Bipolar RF Super High Frequency Microwave Pulmonology, Oncology and Robotics (under development) SpeedboatTM SpydrBladeTM MicroBlateTM • Enabling the switch from surgery under general
Slide 5: Flywheel business model drives compounded revenue growth
Flywheel business model drives compounded revenue growth Strategic value from being at the centre of next generation Clinical studies >20 cases per site minimally invasive surgery Approx Powered by Device / Indication Benefits Region Potential sites Clinical data and Proprietary CROMA: in 2025 Key O
Slide 6: Financial Summary
Financial Summary CREO MEDICAL
Slide 7: H1-25 Highlights
H1-25 Highlights ▪ Robust growth in revenue ▪ Sales from all products such as Speedboat UltraSlim, SpydrBlade, MicroBlade Flex and CROMA platform ▪ 18 new customer additions during the period with focus on increasing utilisation from existing customer base ▪ Strengthened balance sheet and establishe
Slide 8: H1-25 Results: Continuing Revenue
H1-25 Results: Continuing Revenue Revenue up by 40% to £2.2m (H1-24: £1.6m) ▪ Revenue increased by 40% to £2.2m in H1-25 (H1-24: £1.6m) Continuing Revenue £5.0m ▪ Revenues include sales from Speedboat UltraSlim, Speedboat Notch, SpydrBlade, MicroBlade Flex and CROMA platform from existing and new cu
Slide 9: User and Product Adoption drive Accelerating Revenue Growth
User and Product Adoption drive Accelerating Revenue Growth User base – commentary Anticipated user growth Increased utilisation driving procedures per user per year 1000 1000 40 ▪ Growth in user base as Number of procedures per expected to beyond 230 during 800 800 30 2025 with 214 users as at star
Slide 10: H1-25 Results: Operating Costs
H1-25 Results: Operating Costs Underlying operating costs under control ▪ Underlying operating loss decreased to £6.8m (H1-24 £12.0m) due to: Underlying Operating Costs ▪ £0.3m of higher gross margin, £5m reduction going into 2025 has been delivered £30.0m ▪ £3.7m reduction in underlying operating c
Slide 11: Product Strategy and Evolution
Product Strategy and Evolution CREO MEDICAL
Slide 12: Product Roadmap Evolution
Product Roadmap Evolution Product 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Speedboat Launched Inject Speedboat Launched UltraSlim Core Products Speedboat Launched Notch Speedboat Short Launched Market Disruption SpydrBlade Flex Launched * MicroBlate Full commercial Limited Market Release Fi
Slide 13: Target indications in Gastroenterology
Target indications in Gastroenterology Marketed products breaking ground in high-growth indications ESD POEM EUS-guided abalation Resections in the lower and upper GI tract. Includes procedures 1.3 such as Endoscopic Submucosal Dissection (ESD) Millions 1.2 1.1 1 Myotomies and other NOTES procedures
Slide 14: Product Adoption
Product Adoption ▪ Expanded product adoption ▪ Regulatory clearances and commercial launch of SpydrBlade Flex in US, UK and EU ▪ Grew user base and increased clinical adoption with 232 sites globally ▪ Continued growth of Speedboat Notch for advanced procedures such as per-oral endoscopic myotomies
Slide 15: Multi-Author Publication for SpydrBlade Flex
Multi-Author Publication for SpydrBlade Flex ▪ Simplified Zenker’s diverticulum endoscopic myotomy performed with a new bipolar scissor ▪ Compelling clinical report in Endoscopy highlighting an innovative adaptation of the flexible endoscopic myotomy technique (Z-POEM)* for Zenker’s diverticulum. ▪
Slide 16: MicroBlate Flex
MicroBlate Flex ▪ Over 50 global cases completed ▪ Ablate and follow predicted to close enrolment in Q4 ▪ Ablate and resect active in two sites (UK and NL) ▪ Data being presented at largest clinical conference in EU (ERS, Clinical Amsterdam, September 2025) ▪ Registry for collection of post-market d
Slide 17: Summary and Outlook
Summary and Outlook CREO MEDICAL
Slide 18: Summary and Outlook
Summary and Outlook Strong track record of delivering growth Increasing utilisation per user on core products. Speedboat UltraSlim, Revenue Growth - Total SpydrBlade and Speedboat Notch increasing CROMA platform utilisation and £3.0m revenue £2.0m £1.0m Collaborating with Micro-Tech to grow Creo Med
Slide 19: Creo Medical
3EO DICAL Anything is Possible with the Right Approac =